Skip to content
Home/Companies/Biotech/T3 Pharmaceuticals
TP

T3 Pharmaceuticals

Biotech·Switzerland·Exited 2023·Held 4yr

T3 Pharmaceuticals is a biotech company, headquartered in Switzerland.

Entry
2019
Hold
4yr
Exit
2023
Est. EV
–

Who owns T3 Pharmaceuticals?

T3 Pharmaceuticals was owned by Boehringer Ingelheim Venture Fund through Boehringer Ingelheim Venture Fund (2010 vintage) from 2019 to 2023, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-07-07

Boehringer Ingelheim Venture Fund
Investor
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund · 2010 · Evergreen

Key facts

HQSwitzerland
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2023

More from Boehringer Ingelheim Venture Fund

Other portfolio companies in the same fund.

ProTgen
Active
BiotechUnited States· 2024
Refoxy Pharmaceuticals
Active
BiotechGermany· 2024
SwitchKine
Active
BiotechSwitzerland· 2024
Synthetica Pioneering
Active
BiotechChina· 2024
Aurobac Therapeutics
Active
BiotechFrance· 2023
Glox Therapeutics
Active
BiotechUnited Kingdom· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings